RobertMDS Patient

The Right Expression Can Change a Life

When genes are expressed at the wrong time or in the wrong amounts, it alters the function of a cell, leading to disease. By developing small-molecule medicines to control the expression of genes, we aim to make a profound difference in patients’ lives. We are advancing a growing pipeline of investigational gene control medicines for diseases that have largely eluded other genomics-based approaches. Our current focus is on cancer and monogenic diseases.

Program Indication Target Development Drug Discovery IND-Enabling Early Clinical Mid Clinical Pivotal Commercial Rights
SY-1425 (RARα agonist)
SY-1425 (RARα agonist)
Frontline AML (combination with azacitidine)
Target Development Phase complete
Drug Discovery Phase complete
IND-Enabling Phase complete
Early Clinical Phase complete
Mid Clinical Phase in progress
Pivotal Phase not started
Syros (North America & Europe)
Syros (North America & Europe)
SY-1425 (RARα agonist)
Relapsed or refractory AML (combination with azacitidine)
Target Development Phase complete
Drug Discovery Phase complete
IND-Enabling Phase complete
Early Clinical Phase complete
Mid Clinical Phase in progress
Pivotal Phase not started
Syros (North America & Europe)
SY-5609 (Oral CDK7 inhibitor)
SY-5609 (Oral CDK7 inhibitor)
Select solid tumors
Target Development Phase complete
Drug Discovery Phase complete
IND-Enabling Phase complete
Early Clinical Phase in progress
Mid Clinical Phase not started
Pivotal Phase not started
Syros (Global)
Syros (Global)
CDK12/13 Inhibitor
CDK12/13 Inhibitor
Cancer
Target Development Phase complete
Drug Discovery Phase in progress
IND-Enabling Phase not started
Early Clinical Phase not started
Mid Clinical Phase not started
Pivotal Phase not started
Syros (Global)
Syros (Global)
Macrophage Target
Macrophage Target
Cancer/immune modulation
Target Development Phase complete
Drug Discovery Phase in progress
IND-Enabling Phase not started
Early Clinical Phase not started
Mid Clinical Phase not started
Pivotal Phase not started
Syros (Global)
Syros (Global)
LRF & NuRD modulators
LRF & NuRD modulators
Sickle cell disease/beta thalassemia
Target Development Phase complete
Drug Discovery Phase in progress
IND-Enabling Phase not started
Early Clinical Phase not started
Mid Clinical Phase not started
Pivotal Phase not started
GBT (Global; Syros US co-promote option)
GBT (Global; Syros US co-promote option)
Triplet repeat modulator
Triplet repeat modulator
Myotonic dystrophy type 1
Target Development Phase complete
Drug Discovery Phase in progress
IND-Enabling Phase not started
Early Clinical Phase not started
Mid Clinical Phase not started
Pivotal Phase not started
Syros (Global)
Syros (Global)
Discovery
Discovery
Cancer
Target Development Phase in progress
Drug Discovery Phase not started
IND-Enabling Phase not started
Early Clinical Phase not started
Mid Clinical Phase not started
Pivotal Phase not started
Syros (Global)
Syros (Global)
Discovery
Discovery
Myeloproliferative neoplasms
Target Development Phase in progress
Drug Discovery Phase not started
IND-Enabling Phase not started
Early Clinical Phase not started
Mid Clinical Phase not started
Pivotal Phase not started
Incyte (Global)
Incyte (Global)

Interested in Participating in a Clinical Trial?

If you’re interested in participating in a clinical trial, check to see if a trial is open near your area and if you meet the requirements to participate.

Learn More

Partnership Opportunities

We seek partnerships that maximize value for us and our partners by extending the potential of our gene control platform across multiple therapeutic areas and diseases.

View Our Partnership Focus

Our Publications and Abstracts

Learn more about the science and data behind our platform and our programs.

Read Publications and Abstracts